These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome. Coleman CI; Limone BL Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863 [TBL] [Abstract][Full Text] [Related]
43. Prasugrel: Clinical development and therapeutic application. Guerra DR; Tcheng JE Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231 [TBL] [Abstract][Full Text] [Related]
44. Delays of event adjudication in the TRITON trial. Serebruany VL Cardiology; 2010; 115(3):217-20. PubMed ID: 20234133 [TBL] [Abstract][Full Text] [Related]
45. Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes. Aronow WS Postgrad Med; 2013 Jan; 125(1):51-8. PubMed ID: 23391671 [TBL] [Abstract][Full Text] [Related]
46. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Biondi-Zoccai G; Lotrionte M; Agostoni P; Abbate A; Romagnoli E; Sangiorgi G; Angiolillo DJ; Valgimigli M; Testa L; Gaita F; Sheiban I Int J Cardiol; 2011 Aug; 150(3):325-31. PubMed ID: 20828843 [TBL] [Abstract][Full Text] [Related]
47. Late prasugrel benefit in STEMI patients? Serebruany VL Am J Ther; 2009; 16(6):469-70. PubMed ID: 19531932 [TBL] [Abstract][Full Text] [Related]
48. Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. Salisbury AC; Wang K; Cohen DJ; Li Y; Jones PG; Spertus JA Circ Cardiovasc Qual Outcomes; 2013 Jan; 6(1):27-34. PubMed ID: 23212457 [TBL] [Abstract][Full Text] [Related]
49. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD; Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740 [TBL] [Abstract][Full Text] [Related]
50. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. Baker WL; White CM Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817 [TBL] [Abstract][Full Text] [Related]
51. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Held C; Asenblad N; Bassand JP; Becker RC; Cannon CP; Claeys MJ; Harrington RA; Horrow J; Husted S; James SK; Mahaffey KW; Nicolau JC; Scirica BM; Storey RF; Vintila M; Ycas J; Wallentin L J Am Coll Cardiol; 2011 Feb; 57(6):672-84. PubMed ID: 21194870 [TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840 [TBL] [Abstract][Full Text] [Related]
53. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Gurbel PA; Bliden KP; Butler K; Antonino MJ; Wei C; Teng R; Rasmussen L; Storey RF; Nielsen T; Eikelboom JW; Sabe-Affaki G; Husted S; Kereiakes DJ; Henderson D; Patel DV; Tantry US Circulation; 2010 Mar; 121(10):1188-99. PubMed ID: 20194878 [TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361 [TBL] [Abstract][Full Text] [Related]
55. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Norgard NB; Dinicolantonio JJ Postgrad Med; 2013 Jul; 125(4):91-102. PubMed ID: 23933898 [TBL] [Abstract][Full Text] [Related]
56. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. Cannon CP; Husted S; Harrington RA; Scirica BM; Emanuelsson H; Peters G; Storey RF; J Am Coll Cardiol; 2007 Nov; 50(19):1844-51. PubMed ID: 17980250 [TBL] [Abstract][Full Text] [Related]
57. Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease. Koo MH; Nawarskas JJ; Frishman WH Cardiol Rev; 2008; 16(6):314-8. PubMed ID: 18923235 [TBL] [Abstract][Full Text] [Related]
58. Novel antiplatelet agents in development: prasugrel, ticagrelor, and cangrelor and beyond. Shalito I; Kopyleva O; Serebruany V Am J Ther; 2009; 16(5):451-8. PubMed ID: 19262362 [TBL] [Abstract][Full Text] [Related]
59. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963 [TBL] [Abstract][Full Text] [Related]
60. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. Varenhorst C; Alström U; Scirica BM; Hogue CW; Åsenblad N; Storey RF; Steg PG; Horrow J; Mahaffey KW; Becker RC; James S; Cannon CP; Brandrup-Wognsen G; Wallentin L; Held C J Am Coll Cardiol; 2012 Oct; 60(17):1623-30. PubMed ID: 23021325 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]